Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University

Articles by Sagar Lonial, MD, FACP, Winship Cancer Institute of Emory University

Influencing Factors to Initially Targeting BCMA in MM

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

February 1st 2021

Ongoing Approaches Toward Targeting BCMA

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

February 1st 2021

Next Steps for Use of Belantamab in Clinical Practice

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

February 1st 2021

DREAMM-2 Trial Regimen: Safety Updates and Dose Delay

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

January 25th 2021

Management of Ocular Events From DREAMM-2 Regimen

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

January 25th 2021

DREAMM-2 Trial Regimen Safety Profile

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

January 18th 2021

DREAMM-2 Trial Efficacy Data and Recent FDA Approval

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

January 18th 2021

The Rationale for Targeting BCMA in Multiple Myeloma

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

December 18th 2020

Treatment Approach for R/R Multiple Myeloma

BySagar Lonial, MD, FACP, Winship Cancer Institute of Emory University,Asim V. Farooq, MD, University of Chicago Medical Center,Natalie S. Callander, MD, University of Washington Carbone Cancer Center

December 18th 2020

Latest Updated Articles

Influencing Factors to Initially Targeting BCMA in MM
February 1st 2021
Management of Ocular Events From DREAMM-2 Regimen
January 25th 2021
The Rationale for Targeting BCMA in Multiple Myeloma
December 18th 2020
Treatment Approach for R/R Multiple Myeloma
December 18th 2020
DREAMM-2 Trial Regimen: Safety Updates and Dose Delay
January 25th 2021
Next Steps for Use of Belantamab in Clinical Practice
February 1st 2021

Trending on OncLive

Durvalumab Plus Enfortumab Vedotin Improves Survival in Cisplatin-Ineligible MIBC

Adjuvant Intismeran Autogene Plus Pembrolizumab Improves RFS and DMFS in Melanoma

DASL-HiCaP: Darolutamide Plus ADT and Radiation Therapy Improves MFS in Very High-Risk Localized Prostate Cancer

DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC

INCA33890 Plus SOC Elicits Responses and Is Tolerable Across In First- and Third-Line MSS CRC